{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"SNBL to Acquire Satsuma Pharmaceuticals - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"lhnskxAmYz\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/snbl-to-acquire-satsuma-pharmaceuticals\/\">SNBL to Acquire Satsuma Pharmaceuticals<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/snbl-to-acquire-satsuma-pharmaceuticals\/embed\/#?secret=lhnskxAmYz\" width=\"600\" height=\"338\" title=\"&#8220;SNBL to Acquire Satsuma Pharmaceuticals&#8221; &#8212; Market Newsdesk\" data-secret=\"lhnskxAmYz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma\u2019s Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) &#8212; Satsuma Pharmaceuticals, Inc. (\u201cSatsuma\u201d) (Nasdaq: STSA) today announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395, \u201cSNBL\u201d) for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODc3MiM1NTI4Njk4IzUwMDA2OTEyMQ=="}